Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and ...
Valneva shares slump after the companies said the study's primary endpoint didn't meet statistical significance Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine.
Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the ...
Add Yahoo as a preferred source to see more of our stories on Google. The Pfizer company logo is displayed as traders work on the floor of the New York Stock Exchange during morning trading on April ...
Arvinas (ARVN) stock is in focus as the company and Pfizer (PFE) sell global rights to their breast cancer drug, Verzenio, to ...
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...
Sept 8 (Reuters) - Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and ...
Hosted on MSN
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial. The companies said a Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results